Future Aspects of Pharmacotherapy in Erectile Dysfunction

Standard Practice in Sexual Medicine

Volumn , Issue , 2008, Pages 109-114

  Porst, Hartmut ^a  

^a Neuer Jungfernstieg 6a   (Germany)

Author keywords

Clinical investigation; Erectile dysfunction; Erectile function; Neurotransmitters; Pharmaceutical industry; Pharmacotherapy

Indexed keywords

EID: 78149249876     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470755235.ch9     Document Type: Chapter

References (36)

1. Martin WJ, MacIntyre DE. Melanocortin receptors and erectile function. Eur Urol 2004;45:706-713.
2. Wessells H, Fusciarelli K, Hansen J, et al. Melanotropic peptide for the treatment of psychogenic erectile dysfunction: double-blind cross over vehicle controlled study. Int J Impotence Res 1996;8:147.
3. Diamond LE, Earle DC, Rosen RC, et al. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild to moderate erectile dysfunction. Int J Impotence Res 2004;16: 51-59.
4. Rosen RC, Diamond LE, Earle DC, et al. Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with inadequate response to Viagra®. Int J Impotence Res 2004;16:135-142.
5. Wessels H, Padma-Nathan H, Rajfer J, et al. At-home efficacy of an intranasal administered melanocortin receptor agonist, PT-141, in men with erectile dysfunction (ED). J Urol 2004;171:Suppl, 316 Abstr 1197.
6. Diamond LE, Earle DC, Spana C. Co-administration of low doses of intranasal PT 141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction results in an enhanced erectile response. J Urol 2005;Suppl, 287, Abstr 1057.
7. Melis MR, Argiolas A, Gessa GL. Oxytocin-induced penile erection and yawning: sites of action in the brain. Brain Research 1986;415:98-104.
8. Argiolas A, Melis MR, Stancampiano R. Role of central oxytocinergic pathways in the expression of penile erection. Regulatory Peptides 1993;45:139-142.
9. Lidberg L. The effect of syntocinon on patients suffering from impotence. Pharmacopsychiatry 1972;5:187-190.
10. Lidberg L, Sternthal V. A new approach to the hormonal treatment of impotentia erectionis. Pharmacopsychiatry 1977;10:21-25.
11. Jevremovic M, Micic S, Terzic M. The influence of oxytocin on reproductive functions and sexual behavior in males. Int J Impotence Res 1994;6 Suppl.1:P 97.
12. Rehman J, et al. Modification of sexual behaviour of Long-Evans male rats by drugs acting on the 5 HT1A receptor. Brain Res 1999;821:414-425.
13. Rössler A-S, Bernabé J, Alexandre L, et al. Facilitation of proprioceptivity/sexual motivation in female rats by a serotonin 2A/2C (5-HT 2A12C)receptors agonist. J Urol 2005;173:292, Abstr 1077.
14. Hayes ES, Doherty PS, Hanson LA, et al. Pro-erectile effects of novel serotonin agonists. Int J Impotence Res 2000;12 Suppl 3: S62.
15. Song Y, Rajasekaran M. Characterization of hippocampal glutamate receptor subtypes in the central regulation of penile erection. J Urol 2004;171 Suppl, 380:Abstr 1442.
16. Argiolas A, Melis MR, Deghenghi R. EP 91073 prevents EP 80661 induced penile erection: evidence for a specific receptor mediating penile erection for EP peptides in the rat paraventricular nucleus. Int J Impotence Res 2001;13 Suppl 4:S15.
17. Giuliano F, Argiolas A, Bernabé J, et al. Comparison of the pro-erectile effect of two hexarelin analogues EP80661 and EP 91072 with apomorphine after intravenous or intraparaventricular nucleus delivery in anaesthesized rats. Int J Impotence Res 2001;13 Suppl 4:S15.
18. Paick JS, and the DA study group. Efficacy and tolerability of DA-8159 in patients with erectile dysfunction. J Sex Med 2004;1:Suppl 1, 46 O56.
19. Lewis RW, Hellstrom WJG, Gittelman M, et al. Rigiscan evaluation of TA 1790, a novel PDE-5 inhibitor for the treatment of men with erectile dysfunction. J Urol 2004;Suppl, 316, Abstr 1196.
20. Padma-Nathan H, Kim ED, McMurray JG, et al. A novel topical alprostadil cream for the treatment of erectile dysfunction (ED): Combined analysis of two phase 3 pivotal studies. J Urol 2004;171 Suppl, 316 Abstr:1198.
21. Saenz de Tejada I, Cuevas P, Cuevas B, et al. Snitrosylated alpha-blockers as potential drugs for the treatment of impotence:Biological activity of NMI-187 and NMI-221. Int J Impotence Res 8,1996, No 3,103.
22. Cellek S, Kalsi JS, Kell PD, et al. NCX-911,a novel nitricoxide- releasing PDE-5 inhibitor relaxes rabbit corpus cavernosum in the absence of endogenous nitric oxide. Int J Impotence Res 2003;15 Suppl. 6:S25.
23. Christ GJ. Editorial: Membrane bound guanylyl cyclase as a potential molecular target for the treatment of erectile dysfunction. J Urol 2003;169:1923.
24. Küthe A, Reinecke M, Ückert S, et al. Expression of guanylyl cyclase B in the human corpus cavernosum penis and the possible involvement of its ligand C-type natriuretic polypeptide in the induction of penile erection. J Urol 2003;169:1911-1917.
25. Bischoff E, Schramm M, Straub A, et al. BAY 41-2272 a stimulator of soluble guanylyl cyclase induces NOdependent penile erection in vivo. Int J Impotence Res 2002;14 Suppl 3,S43:BSP 10.
26. Brioni JD, Nakane M, Hsieh GC, et al. Activators of soluble guanylate cyclase for the treatment of male erectile dysfunction. Int J Impotence Res 2002; 14:8-14.
27. Kalsi JS, Rees RW, Hobbs AJ, et al. Bay 41-2272, a novel nitric oxide independent soluble guanylate cyclase activator, relaxes human and rabbit corpus cavernosum in vitro. J Urol 2003;169:761-766.
28. Kalsi JS, Ralph DJ, Madge DJ, et al. A comparative study of sildenafil, NCX-911 and BAY 41-2272 on the anococcygeus muscle of diabetic rats. Int J Impotence Res 2004;16:479-485.
29. Chitaley K, Webb RC, Mills TM. The ups and downs of Rho-kinase and penile erection: upstream regulators and downstream substrates of Rho-kinase and their potential role in the erectile response. Int J Impotence Res 2003;15:105-109.
30. Sjunnesson J, Hedlund P, Mizusawa H, Andersson K-E. Inhibition of Rho-associated kinases by Y-27632 produces erectile responses in the mouse. J Urol 2002;167 No 4 Suppl, 238:933.
31. Chang S, Hypolite JA, Changolkar A, et al. Diabetes associated erectile dysfunction: role of endothelin and Rho kinase. J Urol 2002;167 No 4 Suppl 237:932.
32. Wilkes N, White S, Rajasekaran M. PDE-V inhibitors synergizes Rho-kinase antagonism and enhances erectile response in male hypertensive rats. J Urol 2003; 169:No 4 Suppl, 360:1346.
33. Zheng Y, Chang S, Wein AJ, et al. Upregulation of Rho kinase in a human corpus cavernosum smooth muscle cell line in response to hypoxia. J Urol 2004;171 Suppl, 376: Abstr 1429.
34. Mills TM, Chitaley K, Lewis RW. Vasoconstriction in erectile physiology. Int J Impotence Res 2001;13 Suppl. 5:S29-S34.
35. Wilkes N, White S, Cosgrove DJ, Rajasekaran M. Y-27632, an inhibitor of Rho-kinase, improves erectile response in male hypertensive rats. J Urol 2002;167 No 4 Suppl, 238:935.
36. Dai Y, Chitaley K, Webb RC, et al. Topical application of a Rho-kinase inhibitor in rats causes penile erection. Int J Impotence Res 2004;16:294-298.